In a clinical trial of 26 patients with PD‐L1‐positive advanced salivary gland cancer of various histologies, the objective response rate for pembrolizumab monotherapy was only 12%.22 However, additional trials (NCT03360890) are underway with the hope of achieving improved clinical response rates using combination pembrolizumab plus chemotherapy. The gene discussed is CD274; the disease is salivary gland cancer.